Patents by Inventor Yuchun Zhang

Yuchun Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating complement-associated disorders with anti-C5a antibodies
    Patent number: 9469690
    Abstract: The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospholipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: October 18, 2016
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Russell P. Rother, Douglas L. Sheridan, Paul P. Tamburini, Yuchun Zhang
  • NUCLEIC ACIDS ENCODNG ANTI-C5A ANTIBODIES
    Publication number: 20160264654
    Abstract: The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.
    Type: Application
    Filed: May 23, 2016
    Publication date: September 15, 2016
    Inventors: Russell P. ROTHER, Douglas L. SHERIDAN, Paul P. TAMBURINI, Yuchun ZHANG
  • Nucleic acids encodng anti-C5A antibodies
    Patent number: 9434784
    Abstract: The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.
    Type: Grant
    Filed: May 23, 2016
    Date of Patent: September 6, 2016
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Russell P. Rother, Douglas L. Sheridan, Paul P. Tamburini, Yuchun Zhang
  • ANTI-C5A ANTIBODIES
    Publication number: 20160207997
    Abstract: The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospholipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.
    Type: Application
    Filed: April 1, 2016
    Publication date: July 21, 2016
    Inventors: Russell P. ROTHER, Douglas L. Sheridan, Paul P. Tamburini, Yuchun Zhang
  • Anti-C5a antibodies
    Patent number: 9371378
    Abstract: The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: June 21, 2016
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Russell P. Rother, Douglas L. Sheridan, Paul P. Tamburini, Yuchun Zhang
  • ANTI-C5A ANTIBODIES
    Publication number: 20160159892
    Abstract: The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.
    Type: Application
    Filed: February 10, 2016
    Publication date: June 9, 2016
    Inventors: Russell P. ROTHER, Douglas L. Sheridan, Paul P. Tamburini, Yuchun Zhang
  • Nucleic acids encoding anti-C5a antibodies
    Patent number: 9309310
    Abstract: The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospholipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: April 12, 2016
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Russell P. Rother, Douglas L. Sheridan, Paul P. Tamburini, Yuchun Zhang
  • NUCLEIC ACIDES ENCODING ANTI-C5A ANTIBODIES
    Publication number: 20160053004
    Abstract: The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.
    Type: Application
    Filed: November 5, 2015
    Publication date: February 25, 2016
    Inventors: Russell P. Rother, Douglas L. Sheridan, Paul P. Tamburini, Yuchun Zhang
  • Methods of treating complement-associated disorders with anti-C5a antibodies
    Patent number: 9221901
    Abstract: The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: December 29, 2015
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Russell P. Rother, Douglas L. Sheridan, Paul P. Tamburini, Yuchun Zhang
  • ANTI-C5A ANTIBODIES AND METHODS FOR USING THE ANTIBODIES
    Publication number: 20150183859
    Abstract: The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.
    Type: Application
    Filed: March 13, 2015
    Publication date: July 2, 2015
    Applicant: ALEXION PHARMACEUTICALS, INC.
    Inventors: Russell P. ROTHER, Douglas L. SHERIDAN, Paul P. TAMBURINI, Yuchun ZHANG
  • Anti-C5a antibodies
    Patent number: 9011852
    Abstract: The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: April 21, 2015
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Russell P. Rother, Douglas L. Sheridan, Paul P. Tamburini, Yuchun Zhang
  • ANTI-C5a ANTIBODIES AND METHODS FOR USING THE ANTIBODIES
    Publication number: 20130224187
    Abstract: The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.
    Type: Application
    Filed: April 29, 2011
    Publication date: August 29, 2013
    Applicant: ALEXION PHARMACEUTICALS, INC.
    Inventors: Douglas L. Sheridan, Paul P. Tamburini, Yuchun Zhang